Shanghai, November 10th, 2022 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-305, an ADC drug targeting GPRC5D, has been approved by China NMPA.
LM-305 is the second in-house developed ADC drug from LaNova’s proprietary platform. It is currently the 1st anti-GPRC5D biologics drug in China and the 1st anti-GPRC5D ADC to enter clinical stage worldwide.
GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a member of the G protein-coupled receptors (GPCRs) family. As a novel GPCR drug target, GPRC5D is an orphan receptor with no endogenous ligand found. GPRC5D is mainly expressed in malignant bone marrow plasma cells and hair follicles, while in normal tissues, little or no expression is observed. Studies have shown that GPRC5D is specifically highly expressed in patients with multiple myeloma (MM) in a BCMA-independent manner Therefore, GPRC5D has attracted great attention as a key new target in the treatment of MM. As the first GPRC5D-targeting ADC to enter clinical stage, LM-305 has the potential of becoming a First-In-Class molecule.